Bausch Health Companies Inc. (NYSE:BHC) Shares Bought by Creative Planning

Creative Planning boosted its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 16.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 55,351 shares of the company’s stock after acquiring an additional 7,995 shares during the period. Creative Planning’s holdings in Bausch Health Companies were worth $452,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BHC. Headlands Technologies LLC acquired a new position in shares of Bausch Health Companies in the second quarter valued at approximately $35,000. MQS Management LLC acquired a new position in shares of Bausch Health Companies in the second quarter valued at approximately $71,000. Certuity LLC acquired a new position in shares of Bausch Health Companies in the second quarter valued at approximately $75,000. Bfsg LLC raised its position in shares of Bausch Health Companies by 46.7% in the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after buying an additional 3,643 shares during the last quarter. Finally, Kendall Capital Management acquired a new position in shares of Bausch Health Companies in the second quarter valued at approximately $87,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Trading Down 2.0 %

BHC stock opened at $9.50 on Thursday. Bausch Health Companies Inc. has a 52 week low of $3.96 and a 52 week high of $11.46. The company has a market capitalization of $3.49 billion, a price-to-earnings ratio of -19.79 and a beta of 0.74. The firm’s 50-day moving average is $7.76 and its two-hundred day moving average is $7.08.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the previous year, the firm earned $1.03 EPS. Bausch Health Companies’s revenue was up 12.2% on a year-over-year basis. On average, equities research analysts predict that Bausch Health Companies Inc. will post 3.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Royal Bank of Canada boosted their price objective on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. Jefferies Financial Group dropped their price target on shares of Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Truist Financial dropped their price target on shares of Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Raymond James initiated coverage on shares of Bausch Health Companies in a research report on Wednesday, July 10th. They set a “market perform” rating and a $8.00 price target for the company. Finally, StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Bausch Health Companies currently has a consensus rating of “Hold” and an average target price of $7.75.

Insider Transactions at Bausch Health Companies

In other news, EVP Seana Carson sold 13,370 shares of Bausch Health Companies stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $6.21, for a total value of $83,027.70. Following the transaction, the executive vice president now owns 435,198 shares of the company’s stock, valued at $2,702,579.58. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 8.12% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.